At 20.8% CAGR, the Asia Pacific Antibody Drug Conjugates Market is Projected to be Worth US$ 6,971.03 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific antibody drug conjugates market was valued at US$ 1,532.83 million in 2022 and is expected to reach US$ 6,971.03 million by 2030, registering a CAGR of 20.8% from 2022 to 2030. Increasing investments to develop ADCs and increasing FDA approvals are among the critical factors attributed to the Asia Pacific antibody drug conjugates market expansion.

ADCs are a game changer in the field of oncology; these are widely accepted for treating breast cancer. Several companies are making huge investments to develop novel ADCs. In May 2022, Evotec SE announced a huge strategic equity investment in Tubulis GmbH to develop ADCs. Evotec SE has invested US$ 64 million ( 60 million) during Tubliss Series B financing round, which is led by Andera Partners.

According to an article, Antibody-Drug Conjugates: Increasing Investment In R&D And Partnership, published in February 2023, ~63% of ADC developers would actively seek funds and investments in 2023. While ~34% of ADCs will enter into strategic mergers and acquisitions for ADC developments, nearly 56% of companies will make acquisitions of ADC developers. The investments have created broader opportunities for the Asia Pacific antibody drug conjugates market. According to the Hanson Wade Analytics, 57 ADCs entered phase I clinical trials in 2022, accounting for an increase of 20 ADCs from 2021. Moreover, companies are making huge profits through their commercialized products, contributing to market growth for ADCs. For instance, Gilead Sciences, Inc. has gained US$ 22 million in the first quarter of 2023 for its Trodelvy (Sacituzumab govitecan-hziy) that treats HER2-negative metastatic breast cancer. It has experienced an increase of 52% compared to 2022. The increase in profits is also expected to enhance strategic investments and decisions that would expand the market growth shortly.

On the contrary, high cost of ADCs development and commercialization hampers the growth Asia Pacific antibody drug conjugates market.

Based on technology, the Asia Pacific antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 64.9% share of the Asia Pacific antibody drug conjugates market in 2022, amassing US$ 994.58 million. It is projected to garner US$ 4,462.29 million by 2030 to expand at 20.6% CAGR during 2022-2030.

Based on application, the Asia Pacific antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 57.0% share of the Asia Pacific antibody drug conjugates market in 2022, amassing US$ 873.76 million. It is projected to garner US$ 4,091.37 million by 2030 to expand at 21.3% CAGR during 2022-2030.

Based on distribution channel, the Asia Pacific antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 70.6% share of Asia Pacific antibody drug conjugates market in 2022, amassing US$ 1,082.65 million. It is projected to garner US$ 5,044.13 million by 2030 to expand at 21.2% CAGR during 2022-2030.

Based on country, the Asia Pacific antibody drug conjugates market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Japan held 49.1% share of Asia Pacific antibody drug conjugates market in 2022, amassing US$ 752.62 million. It is projected to garner US$ 3,453.45 million by 2030 to expand at 21.0% CAGR during 2022-2030.

Key players operating in the Asia Pacific antibody drug conjugates market are Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd, among others.

- In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.

- In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagens world-class expertise and knowledge of ADC development, manufacturing, and commercialization to maximize the potential of disitamab vedotin.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com